{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T01:36:27Z","timestamp":1769823387397,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008056","name":"Fundaci\u00f3n Florencio Fiorini","doi-asserted-by":"publisher","award":["2023- SI109"],"award-info":[{"award-number":["2023- SI109"]}],"id":[{"id":"10.13039\/100008056","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008056","name":"Fundaci\u00f3n Florencio Fiorini","doi-asserted-by":"publisher","award":["2023- SI109"],"award-info":[{"award-number":["2023- SI109"]}],"id":[{"id":"10.13039\/100008056","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","award":["PUE 2018-574"],"award-info":[{"award-number":["PUE 2018-574"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novartis Argentina 2022","award":["3005351158GR"],"award-info":[{"award-number":["3005351158GR"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01626-x","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T13:31:20Z","timestamp":1742650280000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of leukemic stem cell (CD26\u2009+) in chronic myeloid leukemia patients with different molecular responses and in treatment-free remission"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6148-7563","authenticated-orcid":false,"given":"Mar\u00eda Fernanda","family":"Camacho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margot","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8391-6764","authenticated-orcid":false,"given":"Mar\u00eda Jazm\u00edn","family":"Toloza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Moiraghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1983-6145","authenticated-orcid":false,"given":"Alicia","family":"Enrico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3545-0427","authenticated-orcid":false,"given":"Romina","family":"Mariano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florencia","family":"Negri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Pavlovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Ventriglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Josefina","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"Engelberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Bengi\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6602-4265","authenticated-orcid":false,"given":"Irene","family":"Larripa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"issue":"8","key":"1626_CR1","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","volume":"110","author":"JM Goldman","year":"2007","unstructured":"Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood. 2007;110(8):2828\u201337. https:\/\/doi.org\/10.1182\/blood-2007-04-038943.","journal-title":"Blood"},{"issue":"10","key":"1626_CR2","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343\u201356.","journal-title":"Blood"},{"issue":"4","key":"1626_CR3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ. Response and resistance to BCR::ABL1-targeted therapies. Cancer Cell. 2020;37(4):530\u201342. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.006.","journal-title":"Cancer Cell"},{"issue":"24","key":"1626_CR4","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","volume":"114","author":"MC M\u00fcller","year":"2009","unstructured":"M\u00fcller MC, Cortes JE, Kim DW, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 2009;114(24):4944\u201353. https:\/\/doi.org\/10.1182\/blood-2009-04-214221.","journal-title":"Blood"},{"issue":"14","key":"1626_CR5","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031\u20137. https:\/\/doi.org\/10.1056\/NEJM200104053441401.","journal-title":"N Engl J Med"},{"issue":"5","key":"1626_CR6","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118(5):1208\u201315. https:\/\/doi.org\/10.1182\/blood-2010-12-326405.","journal-title":"Blood"},{"issue":"13","key":"1626_CR7","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","volume":"118","author":"JC Chomel","year":"2011","unstructured":"Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011;118(13):3657\u201360. https:\/\/doi.org\/10.1182\/blood-2011-02-335497.","journal-title":"Blood"},{"issue":"12","key":"1626_CR8","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/eci.12368","volume":"44","author":"P Valent","year":"2014","unstructured":"Valent P, Sadovnik I, R\u00e1\u010dil Z, et al. DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia. Eur J Clin Invest. 2014;44(12):1239\u201345. https:\/\/doi.org\/10.1111\/eci.12368.","journal-title":"Eur J Clin Invest"},{"key":"1626_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.29","author":"NC Cross","year":"2015","unstructured":"Cross NC, White HE, Colomer D, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015. https:\/\/doi.org\/10.1038\/leu.2015.29.","journal-title":"Leukemia"},{"issue":"10","key":"1626_CR10","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NC Cross","year":"2012","unstructured":"Cross NC, White HE, M\u00fcller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26(10):2172\u20135. https:\/\/doi.org\/10.1038\/leu.2012.104.","journal-title":"Leukemia"},{"issue":"1","key":"1626_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28\u201337. https:\/\/doi.org\/10.1182\/blood-2006-01-0092.","journal-title":"Blood"},{"issue":"4","key":"1626_CR12","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u201384. https:\/\/doi.org\/10.1038\/s41375-020-0776-2.","journal-title":"Leukemia"},{"issue":"6","key":"1626_CR13","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384. https:\/\/doi.org\/10.1182\/blood-2013-05-501569.","journal-title":"Blood"},{"issue":"1","key":"1626_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.v99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, J\u00f8rgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99(1):319\u201325. https:\/\/doi.org\/10.1182\/blood.v99.1.319.","journal-title":"Blood"},{"issue":"2","key":"1626_CR15","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2010-08-303495","volume":"119","author":"A Kumari","year":"2012","unstructured":"Kumari A, Brendel C, Hochhaus A, Neubauer A, Burchert A. Low BCR::ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood. 2012;119(2):530\u20139. https:\/\/doi.org\/10.1182\/blood-2010-08-303495.","journal-title":"Blood"},{"issue":"25","key":"1626_CR16","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","volume":"123","author":"H Herrmann","year":"2014","unstructured":"Herrmann H, Sadovnik I, Cerny-Reiterer S, et al. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood. 2014;123(25):3951\u201362. https:\/\/doi.org\/10.1182\/blood-2013-10-536078.","journal-title":"Blood"},{"issue":"8","key":"1626_CR17","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/leu.2016.115","volume":"30","author":"S Sau\u00dfele","year":"2016","unstructured":"Sau\u00dfele S, Richter J, Hochhaus A, Mahon FX. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30(8):1638\u201347. https:\/\/doi.org\/10.1038\/leu.2016.115.","journal-title":"Leukemia"},{"issue":"8","key":"1626_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fonc.2018.00194","volume":"30","author":"M Bocchia","year":"2018","unstructured":"Bocchia M, Sicuranza A, Abruzzese E, et al. Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission. Front Oncol. 2018;30(8):194. https:\/\/doi.org\/10.3389\/fonc.2018.00194.","journal-title":"Front Oncol"},{"issue":"6","key":"1626_CR19","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","volume":"119","author":"A Hamilton","year":"2012","unstructured":"Hamilton A, Helgason GV, Schemionek M, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119(6):1501\u201310. https:\/\/doi.org\/10.1182\/blood-2010-12-326843.","journal-title":"Blood"},{"issue":"1","key":"1626_CR20","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121(1):396\u2013409. https:\/\/doi.org\/10.1172\/JCI35721.","journal-title":"J Clin Invest"},{"issue":"1","key":"1626_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13045-023-01440-6","volume":"16","author":"C Pavlovsky","year":"2023","unstructured":"Pavlovsky C, Vasconcelos Cordoba B, Sanchez MB, et al. Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal. J Hematol Oncol. 2023;16(1):43. https:\/\/doi.org\/10.1186\/s13045-023-01440-6.","journal-title":"J Hematol Oncol"},{"issue":"Supplement 1","key":"1626_CR22","doi-asserted-by":"publisher","first-page":"6365","DOI":"10.1182\/blood-2023-189393","volume":"142","author":"R Tannui","year":"2023","unstructured":"Tannui R, Moiraghi B, Varela A, et al. Long-term follow-up of the AST trial of treatment-free remission in chronic myeloid leukemia patients. Blood. 2023;142(Supplement 1):6365. https:\/\/doi.org\/10.1182\/blood-2023-189393.","journal-title":"Blood"},{"issue":"12","key":"1626_CR23","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of \u201creal-time\u201d quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe against cancer program. Leukemia. 2003;17(12):2318\u201357. https:\/\/doi.org\/10.1038\/sj.leu.2403135.","journal-title":"Leukemia"},{"issue":"1","key":"1626_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","volume":"22","author":"NP Shah","year":"2024","unstructured":"Shah NP, Bhatia R, Altman JK, et al. Chronic myeloid leukemia, Version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(1):43\u201369. https:\/\/doi.org\/10.6004\/jnccn.2024.0007.","journal-title":"J Natl Compr Canc Netw"},{"issue":"17","key":"1626_CR25","doi-asserted-by":"publisher","first-page":"100321","DOI":"10.1016\/j.lrr.2022.100321","volume":"9","author":"HF Ebian","year":"2022","unstructured":"Ebian HF, Abdelnabi AM, Abdelazem AS, Khamis T, Fawzy HM, Hussein S. Peripheral blood CD26 positive leukemic stem cells as a possible diagnostic and prognostic marker in chronic myeloid leukemia. Leuk Res Rep. 2022;9(17):100321. https:\/\/doi.org\/10.1016\/j.lrr.2022.100321.","journal-title":"Leuk Res Rep"},{"issue":"5","key":"1626_CR26","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1111\/ijlh.13528","volume":"43","author":"O Ilhan","year":"2021","unstructured":"Ilhan O, Narli Ozdemir Z, Dalva K, et al. Leukemic stem cells shall be searched in the bone marrow before \u201ctyrosine kinase inhibitor-discontinuation\u201d in chronic myeloid leukemia. Int J Lab Hematol. 2021;43(5):1110\u20136. https:\/\/doi.org\/10.1111\/ijlh.13528.","journal-title":"Int J Lab Hematol"},{"issue":"9","key":"1626_CR27","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1080\/10428194.2017.1421755","volume":"59","author":"J Cui","year":"2018","unstructured":"Cui J, Zhu Z, Liu S, et al. Monitoring of leukemia stem cells in chronic myeloid leukemia patients. Leuk Lymphoma. 2018;59(9):2264\u20136. https:\/\/doi.org\/10.1080\/10428194.2017.1421755.","journal-title":"Leuk Lymphoma"},{"issue":"Supplement 1","key":"1626_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2020-139306","volume":"136","author":"M Bocchia","year":"2020","unstructured":"Bocchia M, Sicuranza A, Pacelli P, et al. Peripheral blood CD26+ leukemia stem cells monitoring in chronic myeloid leukemia patients from diagnosis to response to TKIs: interim results of a multicenter prospective study (prospective flowers). Blood. 2020;136(Supplement 1):45\u20136. https:\/\/doi.org\/10.1182\/blood-2020-139306.","journal-title":"Blood"},{"issue":"12","key":"1626_CR29","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.2147\/CMAR.S232752","volume":"6","author":"C Cumbo","year":"2020","unstructured":"Cumbo C, Anelli L, Specchia G, Albano F. Monitoring of minimal residual disease (MRD) in chronic myeloid leukemia: recent advances. Cancer Manag Res. 2020;6(12):3175\u201389. https:\/\/doi.org\/10.2147\/CMAR.S232752.","journal-title":"Cancer Manag Res"},{"issue":"4","key":"1626_CR30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/cyto.b.21764","volume":"96","author":"D Raspadori","year":"2019","unstructured":"Raspadori D, Pacelli P, Sicuranza A, et al. Flow cytometry assessment of CD26+ leukemic stem cells in peripheral blood: a simple and rapid new diagnostic tool for chronic myeloid leukemia. Cytometry B Clin Cytom. 2019;96(4):294\u20139. https:\/\/doi.org\/10.1002\/cyto.b.21764.","journal-title":"Cytometry B Clin Cytom"},{"issue":"8","key":"1626_CR31","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3389\/fonc.2018.00555","volume":"6","author":"S Galimberti","year":"2018","unstructured":"Galimberti S, Grassi S, Barat\u00e8 C, et al. The polycomb BMI1 protein Is Co-expressed with CD26+ in leukemic stem cells of chronic myeloid leukemia. Front Oncol. 2018;6(8):555. https:\/\/doi.org\/10.3389\/fonc.2018.00555.","journal-title":"Front Oncol"},{"issue":"22","key":"1626_CR32","doi-asserted-by":"publisher","first-page":"33016","DOI":"10.18632\/oncotarget.9108","volume":"7","author":"M Culen","year":"2016","unstructured":"Culen M, Borsky M, Nemethova V, et al. Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects. Oncotarget. 2016;7(22):33016\u201324. https:\/\/doi.org\/10.18632\/oncotarget.9108.","journal-title":"Oncotarget"},{"issue":"17","key":"1626_CR33","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1182\/blood-2016-07-728873","volume":"129","author":"R Warfvinge","year":"2017","unstructured":"Warfvinge R, Geironson L, Sommarin MNE, et al. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. Blood. 2017;129(17):2384\u201394. https:\/\/doi.org\/10.1182\/blood-2016-07-728873.","journal-title":"Blood"},{"issue":"16","key":"1626_CR34","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.3390\/cancers15164112","volume":"15","author":"E Abruzzese","year":"2023","unstructured":"Abruzzese E, Bocchia M, Trawinska MM, et al. Minimal residual disease detection at RNA and leukemic stem cell (LSC) levels: comparison of RT-qPCR, d-PCR and CD26+ stem cell measurements in chronic myeloid leukemia (CML) patients in deep molecular response (DMR). Cancers (Basel). 2023;15(16):4112. https:\/\/doi.org\/10.3390\/cancers15164112.","journal-title":"Cancers (Basel)"},{"issue":"13","key":"1626_CR35","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1182\/bloodadvances.2020001772","volume":"4","author":"P Rousselot","year":"2020","unstructured":"Rousselot P, Loiseau C, Delord M, Cayuela JM, Spentchian M. Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission. Blood Adv. 2020;4(13):3034\u201340. https:\/\/doi.org\/10.1182\/bloodadvances.2020001772.","journal-title":"Blood Adv"},{"issue":"14","key":"1626_CR36","doi-asserted-by":"publisher","first-page":"1194712","DOI":"10.3389\/fphar.2023.1194712","volume":"26","author":"P Pacelli","year":"2023","unstructured":"Pacelli P, Santoni A, Sicuranza A, et al. Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26+ leukemia stem cells. Front Pharmacol. 2023;26(14):1194712. https:\/\/doi.org\/10.3389\/fphar.2023.1194712.","journal-title":"Front Pharmacol"},{"issue":"14","key":"1626_CR37","doi-asserted-by":"publisher","first-page":"1241600","DOI":"10.3389\/fimmu.2023.1241600","volume":"25","author":"MB Sanchez","year":"2023","unstructured":"Sanchez MB, Vasconcelos Cordoba B, Pavlovsky C, et al. In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy. Front Immunol. 2023;25(14):1241600. https:\/\/doi.org\/10.3389\/fimmu.2023.1241600.","journal-title":"Front Immunol"},{"issue":"5","key":"1626_CR38","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41375-021-01238-w","volume":"35","author":"YC Hsieh","year":"2021","unstructured":"Hsieh YC, Kirschner K, Copland M. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape. Leukemia. 2021;35(5):1229\u201342. https:\/\/doi.org\/10.1038\/s41375-021-01238-w.","journal-title":"Leukemia"},{"issue":"3","key":"1626_CR39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/bjh.16718","volume":"191","author":"YD Irani","year":"2020","unstructured":"Irani YD, Hughes A, Clarson J, et al. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. Br J Haematol. 2020;191(3):433\u201341. https:\/\/doi.org\/10.1111\/bjh.16718.","journal-title":"Br J Haematol"},{"issue":"8","key":"1626_CR40","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","volume":"24","author":"A Hughes","year":"2017","unstructured":"Hughes A, Yong ASM. Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol. 2017;24(8):469. https:\/\/doi.org\/10.3389\/fimmu.2017.00469.","journal-title":"Front Immunol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01626-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01626-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01626-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:50:08Z","timestamp":1764917408000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01626-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1626"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01626-x","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"93"}}